MMR and MMRV Vaccines in Pregnancy

MMR and MMRV Vaccines in Pregnancy

• live attenuated viral vaccines, including combined measles, mumps, rubella (MMR) and measles, mumps, rubella, varicella (MMRV) vaccines, contain weakened live viruses
• long-standing clinical guidance advises avoiding live vaccines immediately prior to or during pregnancy due to the theoretical risk of fetal viral transmission (e.g., congenital rubella syndrome or fetal varicella syndrome)
• extensive UK and international surveillance data confirm a complete lack of evidence of risk of harm or congenital abnormalities when live rubella- or varicella-containing vaccines are inadvertently administered in pregnancy

Vaccine Characteristics and Precautionary Advice

• live attenuated composition: MMR and MMRV vaccines contain live attenuated virus strains
• precautionary recommendation: live vaccines are routinely contraindicated during pregnancy or within 1 month prior to conception as a precautionary measure to prevent theoretical teratogenic risks

Safety and Surveillance Evidence

• extensive clinical data: prospective surveillance programmes across the UK, USA, Germany, and large-scale international campaigns evaluated thousands of women inadvertently vaccinated with rubella- or varicella-containing live vaccines shortly before or during pregnancy
• absence of congenital illness: no cases of congenital rubella syndrome (CRS) or fetal varicella syndrome abnormalities have been attributed to inadvertent maternal vaccination
• fetal exposure vs harm: although low-level viral transplacental exposure occurs in a small minority of cases (detected via infant serology), it does not result in fetal malformations, structural toxicity, or adverse pregnancy outcomes
• fetal and maternal safety: inadvertent administration is not associated with an increased risk of miscarriage, stillbirth, or intrauterine growth restriction

Clinical Management of Inadvertent Administration

• non-indication for termination: inadvertent administration of MMR or MMRV vaccine in pregnancy is not a clinical indication for termination of pregnancy
• patient reassurance: clinicians should immediately reassure patients that robust epidemiological evidence demonstrates no proven risk of harm to either the mother or the developing fetus
• clinical documentation: document the inadvertent administration in medical records and report via national surveillance systems (e.g., UKHSA vaccine-in-pregnancy surveillance)

Reference

• UK Health Security Agency (UKHSA). The Safety of MMR and MMRV (Measles, Mumps, Rubella and Varicella) Vaccine when given in Pregnancy: Advice for Healthcare Professionals and Pregnant Women. Guidance document. Updated October 8, 2026.